High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
With this approval, Jemperli is now indicated earlier in treatment, in combination with chemotherapy, for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Jemperli has ...
GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...
(RTTNews) - GSK plc (GSK, GSK.L) announced the FDA has approved Jemperli in combination with carboplatin and paclitaxel followed by Jemperli as a single agent for the treatment of adult patients ...
The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.
(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration expanded the use of its cancer medicine Jemperli, also known as dostarlimab, when combined with chemotherapy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback